Zobrazeno 1 - 10
of 442
pro vyhledávání: '"dipeptidyl-peptidase 4 inhibitors"'
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 2471-2493 (2024)
Rongping Chen,1,* Jing Li,2,* Danqi Chen,3,* Weiheng Wen,1 Susu Zhang,1 Jitong Li,1 Yuting Ruan,1 Zhen Zhang,1 Jia Sun,1 Hong Chen1 1Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republ
Externí odkaz:
https://doaj.org/article/df38dcf4a82f4cf791aed65429204bec
Autor:
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Ivan Pristaš, Ognjen Brborović, Hana Brborović
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract There is a scarcity of information on the population with diabetes mellitus type 2 and cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic medications and COVID-19 outcomes. Study is designed as a retrospec
Externí odkaz:
https://doaj.org/article/ccd5faca0b2744be8ccf749fe414a26a
Autor:
Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana H. Y. Yu, Shawn C. Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R. Shah, Paul E. Ronksley, Lisa M. Lix, Pierre Ernst, Kristian B. Filion, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Publikováno v:
BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Characteristics of patients using newer 2nd and 3rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipe
Externí odkaz:
https://doaj.org/article/4dd7ea64c43847aeb774db5960cf2f58
Autor:
Belen de Nicolas-Ruanes, Asuncion Ballester-Martinez, Emilio Garcia-Mouronte, Emilio Berna-Rico, Carlos Azcarraga-Llobet, Montserrat Fernandez-Guarino
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16786 (2023)
Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane zone. This leads to the activation of complement-dependent and independent p
Externí odkaz:
https://doaj.org/article/68c3724b0d9347448062974a606bfbe9
Autor:
Marija Drakul, Sergej Tomić, Marina Bekić, Dušan Mihajlović, Miloš Vasiljević, Sara Rakočević, Jelena Đokić, Nikola Popović, Dejan Bokonjić, Miodrag Čolić
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16829 (2023)
Sitagliptin, an anti-diabetic drug, is a dipeptidyl peptidase (DPP)-4/CD26 inhibitor with additional anti-inflammatory and immunomodulatory properties. In this study, we investigated for the first time the effect of sitagliptin on the differentiation
Externí odkaz:
https://doaj.org/article/3df9082e493f4885a8d4b1efdbb58b7f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Several new antidiabetic medicines (GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) have been approved by the European Medicines Agency since 2006. The aim of this study was to evaluate the uptake of new antidiab
Externí odkaz:
https://doaj.org/article/fbb2002b5a764158b5e4b61dc9c732a4
Autor:
Florence Hui Sieng Tan, Chin Voon Tong, Xun Ting Tiong, Bik Kui Lau, Yueh Chien Kuan, Huai Heng Loh, Saravanan Vengadesa Pillai
Publikováno v:
Journal of the ASEAN Federation of Endocrine Societies, Vol 36, Iss 2 (2022)
Objective. To evaluate the effect of adding DPP4 inhibitor (DPP4-I) on glycemic variability (GV) in patients with type 2 diabetes mellitus (T2DM) treated with premixed human insulin (MHI). Methodology. We conducted a prospective study in patients w
Externí odkaz:
https://doaj.org/article/2f0222bd7b0c457e900a2d6ef08295d9
Autor:
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-5 (2021)
Abstract Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was t
Externí odkaz:
https://doaj.org/article/51472d51ecc54800893418b0912badfc